- Home
- CMDB vs AVIR Comparison
CMDB vs AVIR Comparison
Compare CMDB & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CMDB | AVIR |
|---|---|---|
| Founded | 2023 | 2012 |
| Country | Monaco | United States |
| Employees | N/A | N/A |
| Industry | | Medicinal Chemicals and Botanical Products |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 456.0M | 399.3M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | CMDB | AVIR |
|---|---|---|
| Price | $18.66 | $4.81 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 63.4K | ★ 365.4K |
| Earning Date | 05-15-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $351,367,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.81 | $2.78 |
| 52 Week High | $20.50 | $6.45 |
Technical Indicators
Market Signals| Indicator | CMDB | AVIR |
|---|---|---|
| Relative Strength Index (RSI) | 52.26 | 52.23 |
| Support Level | $16.18 | $4.14 |
| Resistance Level | $19.84 | $5.04 |
| Average True Range (ATR) | 0.81 | 0.23 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 42.99 | 46.39 |
Price Performance
Historical ComparisonAbout CMDB Costamare Bulkers Holdings Limited
Costamare Bulkers Holdings Ltd is an international owner and operator of dry bulk vessels providing transportation of dry bulk commodities globally for a broad range of customers. Its vessels transport a broad range of bulks, such as iron ore, coal and grains and minor bulks, such as bauxite, phosphate fertilizers and steel products, across shipping routes globally. The company's vessel fleet includes Current Dry Bulk Fleet, Chartered-In Vessels Fleet, and Chartered-In Newbuilding Vessels. It operates under one reportable segment, that of operating dry bulk vessels.
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of oral antiviral therapies for serious viral diseases. The company's pipeline includes a regimen of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV) infection and AT-587 for the treatment of hepatitis E virus (HEV) infection.